Liquid Crystal Hemostatic Formulations for Rapid Bleeding Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hemostatic agents and devices face limitations in effectively establishing hemostasis without causing secondary immunologic responses and have limited efficacy in controlling biological fluids, especially in achieving rapid and reliable results.
Innovation Solution
Development of hydrophilic or amphiphilic liquid crystalline formulations containing liquid-crystal forming compounds, which can be designed for positive-pressure application, in situ activation, and biodegradability, incorporating fatty acids to increase viscosity, and combining with solvents like normal saline or whole blood to enhance their hemostatic and wound-healing properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional hemostatic agents (astringents, hydrolyzed gelatin, oxidized cellulose) are used to establish hemostasis, then hemostatic effect is achieved, but secondary immunologic responses and limited efficacy occur
Solution Approach 1:
The invention changes the physical state parameter of the hemostatic formulation from conventional solid or liquid forms to a liquid crystalline phase. This parameter change enables the formulation to exhibit both liquid-like flow properties for easy application and solid-like structural organization for enhanced hemostatic activity, thereby improving reliability while avoiding harmful immunologic responses associated with conventional agents
Solution Approach 2:
The invention employs composite materials by combining liquid-crystal forming compounds with solvents (such as normal saline, whole blood, or plasma) to create a novel formulation system. This composite approach integrates the structural benefits of liquid crystals with the physiological compatibility of biological fluids, achieving reliable hemostasis without triggering secondary immunologic responses
2Reliability
If liquid-crystal forming compounds are formulated with high concentration to improve hemostatic control, then viscosity and firmness increase, but application difficulty may arise
Solution Approach 1:
The invention applies dynamics by formulating the composition to exist in a liquid crystalline phase that can dynamically adapt its physical properties. The formulation maintains flowability for easy application but transitions to a more structured state upon contact with biological fluids, providing reliable control without compromising application ease
Solution Approach 2:
The invention utilizes parameter changes by controlling the physical state of the formulation through temperature, composition, and phase transitions. The liquid crystalline formulation can be applied in a fluid state and then transitions to a more viscous or gel-like state at the application site, ensuring both ease of operation and reliable biological fluid control
3Stability of the object's composition
If fatty acids are added to liquid-crystal forming compounds to increase viscosity, then firmness of the liquid crystal phase increases, but formulation complexity increases
Solution Approach 1:
The invention merges multiple functions into a single component by selecting liquid-crystal forming compounds that inherently provide both the liquid crystalline phase structure and the desired firmness. Fatty acids are integrated as part of the liquid-crystal forming compound structure rather than separate additives, thereby increasing stability without significantly increasing formulation complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations effectively control bleeding, promote hemostasis, prevent adhesions, and inhibit microbial infections, providing rapid and sustained effects while minimizing adverse immune responses, with applications in surgical and cosmetic medical uses.
Implementation Method 1
controlling biological fluids, certain formulations of liquid-crystal forming compounds demonstrate advantageous utilities including: promoting hemostasis; the compositions and formulations provide excellent toxicity, sensitization and irritation profiles
Implementation Method 2
certain fatty acids, when added to certain formulations of liquid-crystal forming compounds, increase the viscosity or firmness of the highly viscous liquid crystal phase once formed
Implementation Method 3
The inventors have discovered that at least in part by controlling biological fluids, certain formulations of liquid-crystal forming compounds demonstrate advantageous utilities including: promoting hemostasis
Implementation Method 4
providing barriers to seal tissues and prevent adhesions
Implementation Method 5
promoting tissue growth; promoting wound healing
Implementation Method 6
inhibiting microbial infections
Data Source
AI summary
Therapeutic formulations adapted for positive-pressure application for controlling biological fluid at a desired site in a subject, absorbent articles comprising therapeutic formulations, and anti-infective devices coated with therapeutic formulations, said formulations comprising about 25% to about 99% by weight liquid-crystal forming compound and 0% to about 75% by weight solvent. In addition, methods of using said formulations including methods for controlling biological fluid at a desired site in a subject, methods for controlling blood loss, and methods for facilitating effective closure of a vascular wound or incision site at a desired site in a subject are disclosed, the methods comprising administering particular formulations comprising liquid-crystal forming compounds and solvents that are described herein.